Abstract:In the author's institution, 2254 patients with hepatocellular carcinoma (HCC) have been treated during 1958-1994. The overall 5-year survival increased from 5.4% (1958-1970), to 11.9% (1971-1982), to 46.2% (1983-1984), which correlated well with the increasing proportion of small HCC in the series (2.6%, 12.1%, and 33.4%, respectively); with the increasing percentage of limited resection (3.1%, 32.2%, and 58.3%); with the increasing number of re-resections for recurrence (0, 27, and 114 patients); and with the increasing number of second stage resections (0, 5, and 67 patients). In our institution, surgical approaches that resulted in significantly prolonging survival included: small HCC resection, re-resection, and cytoreduction followed by sequential resection for initially unresectable HCC. Experience in these 3 aspects suggests: (a) Small HCCs are mainly found by screening using AFP and ultrasonography (US) in a high risk population, and limited resection is the best treatment in patients with compensated liver cirrhosis, the 5-year survival after resection being 62.9% (n = 549). (b) Postoperative monitoring using AFP/US every 2-3 months for 5-10 years after curative resection is needed to detect subclinical recurrence. Limited re-resection is indicated for liver recurrence less than 3 nodules, and lung lobectomy is of proven merit to prolong survival for solitary lung metastasis. Re-resection of subclinical recurrence has resulted in a 10-20% further increase in 5-year survival after curative resection. (c) Palliative surgery other than resection such as hepatic artery ligation (HAL) and cannulation with arterial infusion (HAI), cryosurgery, etc. are superior to palliative resection with residual cancer. (d) Cytoreduction and sequential resection have provided hope for localized unresectable HCC, particularly in the right cirrhotic liver. Multimodality combination treatments such as HAL+HAI+radioimmunotherapy/regional radiotherapy are acceptable cytoreductive therapies. Repeated transcatheter hepatic arterial chemoembolization (TACE) is an alternative nonsurgical approach. Sequential resection is important to eradicate residual cancer after cytoreduction. The 5-year survival of 72 patients with cytoreduction and sequential resection for initially unresectable HCC was 62.1% and resulted in improving 5-year survival in the entire series of unresectable HCC over the 3 periods from 0% to 7.4% to 25.7%, respectively. However, multicentric origin and tumor invasiveness are two major targets to be studied in the control of recurrence and metastasis.

The Role of Targeting Therapy in Cytoreduction and Sequential Resection of Unresectable Hepatocellular Carcinoma

Cytoreduction and Sequential Resection for Surgically Verified Unresectable Hepatocellular Carcinoma: Evaluation with Analysis of 72 Patients

Three Decades' Experience In Surgery Of Hepatocellular Carcinoma

Conversion of Surgically Verified Unresectable to Resectable Hepatocellular Carcinoma

Sequential Transcatheter Arterial Chemoembolization, Three-Dimensional Conformal Radiotherapy, and High-Intensity Focused Ultrasound Treatment for Unresectable Hepatocellular Carcinoma Patients

Multimodality treatment and two-stage resection for unresectable hepatocellular carcinoma--experimental and clinical studies]

Resection of huge hepatocellular carcinoma by two-stage operation: Report of 48 cases

Sequential Resection after Cytoreduction of Unresectable Hepatocellular Carcinoma and Factors Influencing Survival of Patients

INTRAHEPATIC ARTERIAL I-131 ANTI-HEPATOCELLULAR CARCINOMA (HCC) MONOCLONAL-ANTIBODY COMBINED WITH HEPATIC-ARTERY LIGATION FOR TREATMENT OF UNRESECTABLE HCC

Treatment of unresectable primary liver cancer: With reference to cytoreduction and sequential resection

[Influence of Different Treatment Modalities on Survival of Patients with Two -Stage Resection of Unresectable Hepatocellular Carcinoma].

Surgical Treatment of Recurrent Hepatocellular Carcinoma.

Cytoreduction and Sequential Resection - A Hope for Unresectable Primary Liver-Cancer

An Approach Improving Long-Term Outcome of Surgery for Hepatocellular Carcinoma: Analysis of 113 Patients Surviving More Than Five Years

Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma

Current Status of Multimodal & Combination Therapy for Hepatocellular Carcinoma.

Initially Unresectable Hepatocellular Carcinoma Treated by Combination Therapy of Tyrosine Kinase Inhibitor and Anti-Pd-1 Antibody Followed by Resection.

Triple Combination Therapy Comprising Angiogenesis Inhibitors, Anti-Pd-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma.

Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma